Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma

Official Title

A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial)


This is a multi-centre, open-label, single arm phase 2 study to assess the efficacy of TRIFLURIDINE/TIPIRACIL, in patients with advanced cholangiocarcinoma as measured by median progression-free survival (PFS). This study will enroll a total of 47 patients over a 12-month period, according to a two stage enrollment design. Nine patients will be enrolled during the first stage and the trial will be terminated if 4 or more out of the 9 have disease progression. If the trial goes on to the second stage, a total of 47 patients (38 in second stage) will be required. Patients will be seen prior to enrolment (within 28 days of treatment), every 4 weeks while on treatment, at the end of treatment, and 30 days post-treatment. Patients will remain on long-term follow-up and will be seen every 12 weeks (+/- 14 days) until 1 year post-treatment when they will enter into the survival follow-up period and will be contacted every 12 weeks by phone until progression or toxicity.

Trial Description

Primary Outcome:

  • Median progression-free survival (PFS)
Secondary Outcome:
  • Safety and tolerability of FTD/TPI: CTCAE version 5.0
  • Disease Control Rate (Complete Response, Partial Response, Stable Disease) of FTD/TPI
  • Duration of response of FTD/TPI
  • Median overall survival of patients with cholangiocarcinoma treated with FTD/TPI.
  • Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society